Eventus Diagnostics
Blood Test for Breast Cancer Diagnosis
Company Overview
Snapshot
Founded in June 2010 by Alon Hayka and Marvin Rosenberg, Eventus Diagnostics operates with 11–50 employees. The company has raised $2.72M across one funding round. In April 2014, EventusDx completed a $2.72M financing round to support the development and commercialization of its Octava breast cancer tests.
Business overview
Eventus Diagnostics is a life sciences company focused on developing accurate and cost-effective blood tests for cancer-specific autoantibodies. The company's core products, Octava Pink and Octava Blue tests, provide diagnostic information to enhance the validity of mammography screening results for breast cancer. These tests aim to confirm true negative findings, identify cancer in cases of false negatives, and reduce unnecessary biopsies caused by false positives, serving the healthcare and medical devices sectors, particularly laboratories and providers in the United States, Europe, and Israel.
Strategic signal
In June 2014, Eventus Diagnostics was highlighted for its breakthrough in developing the first blood test for breast cancer. This development signals a significant advancement in early cancer detection, offering a less invasive and potentially more accurate diagnostic tool. For investors and innovation teams, this indicates the company's potential to disrupt traditional breast cancer screening methods and improve patient outcomes, validating its innovative approach in the health tech and life sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Eventus Diagnostics' primary focus?
- Eventus Diagnostics is primarily focused on developing accurate and cost-effective blood tests that measure cancer-specific autoantibodies for the diagnosis of breast cancer.
- When was Eventus Diagnostics founded and by whom?
- Eventus Diagnostics was founded in June 2010 by Alon Hayka and Marvin Rosenberg.
- What are the key products offered by Eventus Diagnostics?
- The company offers Octava Pink and Octava Blue tests, which provide additional diagnostic information to assess mammography screening results for breast cancer.
- What was a significant financial milestone for Eventus Diagnostics?
- In April 2014, EventusDx completed a $2.72M financing round to support the development and commercialization of its Octava breast cancer tests.
- What problem do the Octava tests aim to solve?
- The Octava tests aim to improve breast cancer diagnosis by confirming mammography results, identifying false negatives, and reducing unnecessary biopsies caused by false positives.